-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KcVUc0HyTKh/LyQLY97QtYInEREgw98KgS/wbwZRmzIuT5el++hZJKtDAmpsLQ7d e/ZNr8CH/7zm6+YhEl5sfQ== 0001240015-04-000029.txt : 20041027 0001240015-04-000029.hdr.sgml : 20041027 20041027173550 ACCESSION NUMBER: 0001240015-04-000029 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041026 FILED AS OF DATE: 20041027 DATE AS OF CHANGE: 20041027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VASICEK THOMAS J CENTRAL INDEX KEY: 0001240017 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22570 FILM NUMBER: 041100381 BUSINESS ADDRESS: STREET 1: 25861 INDUSTRIAL BLVD CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LYNX THERAPEUTICS INC CENTRAL INDEX KEY: 0000913275 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 943161073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 25861 INDUSTRIAL BLVD CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 MAIL ADDRESS: STREET 1: 25861 INDUSTRIAL BLVD CITY: HAYWARD STATE: CA ZIP: 94545 4 1 edgar.xml PRIMARY DOCUMENT X0202 4 2004-10-26 0000913275 LYNX THERAPEUTICS INC LYNX 0001240017 VASICEK THOMAS J 25861 INDUSTRIAL BLVD. HAYWARD CA 94545 0 1 0 0 VP, Business Development Employee Stock Option (right to buy) 2.96 2004-10-26 4 A 0 2500 2.96 A 2004-10-26 2014-10-26 Common Stock 2500 2500 D poa: Kathy A. San Roman 2004-10-27 EX-24 2 powerofattorney.htm
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Kevin P. Corcoran, Edward C. Albini and Kathy A. San Roman, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of Lynx Therapeutics, Inc. ("Lynx"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Lynx assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Lynx, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by Lynx.

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 16th day of September 2002.



/s/  Thomas J. Vasicek

 Thomas J. Vasicek





















247948 v2/HN

5bbg02!.DOC 2.







247948 v2/HN

5bbg02!.DOC



-----END PRIVACY-ENHANCED MESSAGE-----